- Details
- Alexander Laird joins Sam Chang in conversation to discuss data aimed at identifying clinical and radiological factors that could predict upper tract urothelial carcinoma to avoid diagnostic ureteroscopy in selected patients. The study found that patients with a final diagnosis of upper tract urothelial carcinoma tended to be older, smokers, had a history of previous abdominal surgery, presented w...
|
- Details
- Min Yuen Teo joins Sam Chang in a discussion on an ongoing Phase II clinical trial on neoadjuvant immune checkpoint inhibition, with both a combination of nivolumab and ipilimumab in patients with high grade invasive upper tract urothelial cancer who are cisplatin-ineligible. It was designed as a Phase II study with a two stage design. The study's primary endpoint was pathologic complete response;...
|
- Details
- Wesley Yip and Jonathan Coleman join Sam Chang in a conversation discussing the impact of neoadjuvant chemotherapy prior to radical nephroureterectomy and its possible benefit on patients with high-grade upper tract urothelial carcinoma. Upper tract urothelial carcinoma is rare but deadly, with 5-year cancer-specific mortality rates of 21-59%. High-grade disease defines a high-risk population, and...
|
- Details
- Daniel Joyce joins Sam Chang to discuss oncologic outcomes, costs, and quality metrics for patients with both synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC). Upper tract urothelial carcinoma accounts for around 10% of all urothelial cancer cases that appear. Just around half of those will develop metastatic illness. This work's main objective was to determine what...
|
- Details
- Marco Moschini joins Sam Chang in a discussion on highlighting a European Urology Oncology publication that sought to review the available literature systematically focused on incidence, diagnosis, clinicopathological features, oncological outcomes, and screening protocols for upper tract urothelial carcinoma (UTUC) among Lynch syndrome patients. This study aims to reduce misdiagnosis and improve...
|
- Details
- Sam Chang and Paolo Gontero discuss the updated EAU guidelines for upper tract urothelial carcinoma (UTUC), focusing on three main topics that have been subject to revision. Drs. Gontero and Chang discuss the relationship between UTUC and genetics and the recommendation that patients presented with UTUC should receive a medical history that is focused on ruling out Lynch syndrome prompting germlin...
|
- Details
- Sam Chang is joined by Katherine Fero and Stephen Williams to discuss their work evaluating the treatment patterns, costs, and survival outcomes among patients with nonmetastatic upper tract urothelial carcinoma (UTUC) in the United States. This research sought to look at and see how contemporarily patients are being managed with a real-world study sample looking at treatment patterns and then the...
|
- Details
- Francesco Del Giudice and Ben Chung join Sam Chang in a discussion on addressing the contemporary trends of systemic neoadjuvant and adjuvant intravesical chemotherapy for upper tract urothelial carcinomas undergoing minimally invasive or open radical nephroureterectomy focused on a large insurance claim dataset from the United States. In this conversation, Francesco Del Giudice, and Ben Chung spe...
|
- Details
- Firas Petros, Urologic Oncologist from the University of Toledo College of Medicine joins Sam Chang in reviewing practice-changing and hypothesis-generating abstracts from the upper tract urothelial carcinoma podium session at the 2022 Annual Meeting of the American Urological Association (AUA). Dr. Petros first highlights two abstracts that involved the use of circulating tumor DNA as a biomarker...
|
- Details
- Surena Matin, Jonathan Coleman, and Jean Hoffman-Censits join Sam Chang in a case-based discussion on approaches to the treatment of upper tract disease. The group evaluate a 75 years old, former smoker, who develops painless gross hematuria. His CT shows a 3-centimeter, left upper pole filling defect with a soft tissue mass. Labs are essentially normal. GFR is 65. The patient has good performance...
|
